[Optimization of treatment focal forms of epilepsy in young children]

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology
• Epileptology

Background:

• Focal epilepsy is a common neurological disorder in children.
• Treatment options for pediatric focal epilepsy require evaluation for efficacy and safety.
• Topiramate is an anticonvulsant medication with potential applications in pediatric epilepsy management.

Purpose of the Study:

• To assess the efficacy of Topamax (topiramate) in treating focal epilepsy in children.
• To evaluate the safety and tolerability profile of topiramate in this pediatric population.

Main Methods:

• A clinical trial involving 30 children (24-46 months) with focal epilepsy.
• Patients were stratified into symptomatic and cryptogenic focal epilepsy groups.
• Topiramate was administered as monotherapy or combined therapy with a mean dose of 5.9 mg/kg/day for 6 months.

Main Results:

• A positive treatment outcome (seizure cessation or ≥50% reduction) was observed in 19 (63.75%) patients after 6 months.
• Nine (29.5%) patients showed minimal or no response to the treatment.
• Adverse events occurred in 11 (36%) patients, with 5 (16%) discontinuing treatment due to side effects like vomiting and increased seizure frequency.

Conclusions:

• Topiramate demonstrates significant efficacy in reducing seizure frequency in children with focal epilepsy.
• While generally effective, careful monitoring for adverse events is crucial due to potential side effects.
• Topiramate can be a valuable therapeutic option for pediatric focal epilepsy, but individualized treatment approaches are necessary.